Key facts
- Kalderos’s last known valuation is $170.0M (Sep 2022).
- It has raised $108.5M across 4 recorded rounds; the latest was Early Stage VC ($26.4M) in Dec 2024.
- Notable investors include Alumni Ventures, TriplePoint Capital, Bain Capital Ventures, New Leaf Venture, Savano Capital Partners — 7 tracked in total.
- Kalderos has filed 4 Form Ds with the SEC since 2019, most recently Jan 2025 ($26.4M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Kalderos
Funding rounds
4 roundsAbout Kalderos
Developer of medicine management platform designed to analyze the complex coordination of drug discount programs. The company's platform offers data management, provides clear and customizable views into the data available in the cloud with immediate access to targeted insights and offers claims verification, dispute resolution and discount monitoring, enabling clients to get a streamlined process for communicating, verifying and payment.
- Sector
- Information Technology
- HQ
- Chicago, IL, United States
- Founded
- 2016
- Employees
- 127
- Website
- kalderos.com/
- Ownership
- Privately Held (backing)
Kalderos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kalderos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kalderos in its N-PORT filings yet. We sweep new filings monthly.